The Life Sciences team advised Moderna, Inc. (“Moderna”) on a strategic collaboration with Recordati to advance Moderna's investigational propionic acidemia (PA) therapeutic, mRNA-3927, through the final stages of clinical development and, upon approval, global commercialization. Recordati, based in Milan, Italy, is an international pharmaceutical group that provides treatments across specialty and primary care, and rare diseases, including PA. Through this agreement, Moderna will continue to lead the clinical development of mRNA-3927 through approval and Recordati will lead commercialization.
Under the terms of the agreement, Moderna will receive an upfront payment of $50 million and up to an additional $110 million in near-term development and regulatory milestones, in addition to commercial and sales milestones and tiered royalties on net sales.
Moderna is a pioneer and leader in the field of mRNA medicine. Through the advancement of its technology platform, Moderna is reimagining how medicines are made to transform how we treat and prevent diseases. Since its founding, Moderna's mRNA platform has enabled the development of vaccines and therapeutics across infectious diseases, cancer, rare diseases and more. With a global team and a unique culture, driven by the company's values and mindsets, Moderna's mission is to deliver the greatest possible impact to people through mRNA medicines.
The Goodwin team was led by Felipe Heiderich, Stuart Cable, Kingsley Taft, and Austin Church (Life Sciences), Dan Karelitz (Tax), Susan Lee (FDA), Paul Jin and Kevin Walsh (Antitrust), with invaluable support from Sarah Solomon and Frank Qin.
For more information on the deal, please read the press release.